反tau单域抗体清除病态tau,减轻其毒性和相关的功能缺陷
Sudershana Nair1,2, Yixiang Jiang1, Isabella S Marchal1,2
1Department of Neuroscience and Physiology, Neuroscience Institute, New York University Grossman School of Medicine, New York, NY, USA.
Cell death & disease
|July 30, 2024
概括
研究人员开发了新的反单域抗体 (sdAbs) 来对抗病. 一种强大的sdAb通过清除病态tau和改善Drosophila模型中的神经元功能来证明了显著的治疗潜力,支持基因治疗的发展.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
背景情况:
- 病是一种神经退行性疾病,由异常的蛋白聚合物定义.
- 开发有效的定位疗法仍然是神经科学中的一个关键挑战.
研究的目的:
- 开发和评估新型单域抗体 (sdAbs),以了解它们对病的治疗潜力.
- 在Drosophila melanogaster型陶病症模型中评估选择的抗tau sdAbs的疗效.
主要方法:
- 在拉玛免疫接种后,使用菌体显示技术生成了50多个反tau sdAbs.
- 在Drosophila tauopathy模型中转基因表达了四种有前途的sdAbs,以评估它们的治疗效果.
- 通过各种测定测量病理性tau清除,神经保护和功能恢复来评估sdAb的有效性.
主要成果:
- 在四种测试的sdAbs中,有三种在清除病态tau方面表现出显著的治疗潜力.
- 这些sdAbs减弱或防止tau诱导的表型,包括轴突运输缺陷,神经退行和寿命缩短.
- 一个sdAb在所有测试中表现出优异的性能,这可能是由于其特定的陶结合表位.
结论:
- 开发的抗陶氏体SDAbs显示出作为一种新的治疗策略来治疗陶氏体病.
- 由于其已证明的疗效和安全性,主导的sdAb候选物值得进一步开发为治疗病的基因疗法.
相关概念视频
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456


